Open-label: the clinical effects of adding cannbidiol to usual care of patients with residual symptoms in the diagnosis of Obsessive Compulsive Disorder (2023)
- Authors:
- USP affiliated authors: ZUARDI, ANTONIO WALDO - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; OSORIO, FLAVIA DE LIMA - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; MORAIS, EDER ROBERTO DE - FMRP
- Unidade: FMRP
- DOI: 10.1192/j.eurpsy.2023.524
- Subjects: CANABINOIDES; TRANSTORNO OBSESSIVO-COMPULSIVO; SINTOMAS PSÍQUICOS; PSICOMETRIA
- Language: Inglês
- Imprenta:
- Source:
- Título: European Psychiatry
- ISSN: 0924-9338
- Volume/Número/Paginação/Ano: v. 66, suppl 1, p. S225-S226, abst. EPP0193, 2023
- Conference titles: European Congress of Psychiatry
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MORAIS , Eder Roberto de et al. Open-label: the clinical effects of adding cannbidiol to usual care of patients with residual symptoms in the diagnosis of Obsessive Compulsive Disorder. European Psychiatry. Cambridge: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1192/j.eurpsy.2023.524. Acesso em: 27 jan. 2026. , 2023 -
APA
Morais , E. R. de, Zuardi, A. W., Guimarães, F. S., Osório, F. de L., Hallak, J. E. C., Sanches, R. F., & J. A. S. Crippa,. (2023). Open-label: the clinical effects of adding cannbidiol to usual care of patients with residual symptoms in the diagnosis of Obsessive Compulsive Disorder. European Psychiatry. Cambridge: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1192/j.eurpsy.2023.524 -
NLM
Morais ER de, Zuardi AW, Guimarães FS, Osório F de L, Hallak JEC, Sanches RF, J. A. S. Crippa. Open-label: the clinical effects of adding cannbidiol to usual care of patients with residual symptoms in the diagnosis of Obsessive Compulsive Disorder [Internet]. European Psychiatry. 2023 ; 66 S225-S226.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1192/j.eurpsy.2023.524 -
Vancouver
Morais ER de, Zuardi AW, Guimarães FS, Osório F de L, Hallak JEC, Sanches RF, J. A. S. Crippa. Open-label: the clinical effects of adding cannbidiol to usual care of patients with residual symptoms in the diagnosis of Obsessive Compulsive Disorder [Internet]. European Psychiatry. 2023 ; 66 S225-S226.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1192/j.eurpsy.2023.524 - Cannabinoids for the treatment of mental disorders [Carta]
- Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
- Impact of cognitive deficits in patients with cirrhosis and alcoholic hepatopathy after reduction in alcohol intake. [Carta]
- Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?
- Effects of minocycline on regional cerebral blood flow in schizophrenia
- Possible therapeutic uses of cannabidiol in anxiety disorders and schizophrenia
- Cannabidiol, a cannabis sativa constituent, as an antipsycholic drug
- Canabidiol: possíveis aplicacões terapêuticas em psicopatologias
- A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
- Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder
Informações sobre o DOI: 10.1192/j.eurpsy.2023.524 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003249628.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
